Clinical Trial Update: Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial exploring armatinib alone or with SRT for brain metastases in EGFR-mutated non-small cell lung cancer; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Armatinib (armatinin? (exact generic name not provided))

Snippet

Sponsor: Shanghai Cancer Hospital, China | Conditions: Non-small Cell Lung Cancer Metastatic | Phase 3 | Status: RECRUITING